Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 19/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16980439 | 0.91 | DPP4 (0.41) | OPRL1OPRM1OPRK1OPRD1DPP4 | |
| SCHEMBL20756988 | 0.91 | OPRL1 (0.38) | OPRL1OPRM1OPRK1OPRD1DPP4 | |
| SCHEMBL18664010 | 0.91 | OPRL1 (0.38) | OPRL1OPRM1OPRK1OPRD1DPP4 | |
| SCHEMBL27290705 | 0.89 | DPP4 (0.44) | OPRL1OPRM1OPRK1OPRD1DPP4 | |
| SCHEMBL23252446 | 0.87 | ALDH1A1 (0.42) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL10217307 | 0.87 | ALDH1A1 (0.42) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL20858038 | 0.86 | ALDH1A1 (0.37) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL20756541 | 0.86 | HRH3 (0.35) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL12458632 | 0.86 | HRH3 (0.35) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL20756551 | 0.86 | OPRL1 (0.34) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | OPRL1 4502/4885OPRM1 3619/4885OPRK1 3829/4885 |
| US-11690915-B2 | Ras inhibitors | KRAS, NRAS, HRAS | OPRL1 4495/4885OPRM1 4301/4885OPRK1 4221/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | OPRL1 4502/4885OPRM1 3619/4885OPRK1 3829/4885 |
| US-20230226186-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | OPRL1 4495/4885OPRM1 4301/4885OPRK1 4221/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | OPRL1 4309/4885OPRM1 4485/4885OPRK1 4239/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | OPRL1 4495/4885OPRM1 4301/4885OPRK1 4221/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | OPRL1 4495/4885OPRM1 4301/4885OPRK1 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.